关于HR医药商业集团并购绩效的研究

发布时间：2018-02-27 05:20

本文关键词： 并购绩效医药行业因子分析法　出处：《北京化工大学》2015年硕士论文　论文类型：学位论文

【摘要】：随着2009年新医改方案公布,国家希望加快医药行业管理的升级和产业集中度的提高。在如此的大环境之下,我国医药公司呈现出兼并收购的趋势。因此,研究医药企业的综合并购绩效、科学分析评价其并购绩效尤为重要,它是衡量医药企业并购成功与否的关键所在,评价制度和体系可以帮助企业提高对并购绩效的了解。只有完善企业的并购制度,提高企业的并购绩效,才能真正增强其核心竞争力,在实现战略目标的同时为企业创造更多的财富价值。该选题具有一定的理论研究意义与现实实践意义。全篇共分为六部分。首先,主要介绍本论文选题背景意义、研究内容和方法、创新点和局限性。其次对并购的概念进行界定,同时介绍并购绩效的理论研究基础和关于并购绩效的国内外研究现状。第三,分析我国医药行业现阶段并购发展状况,包括并购制度背景、现状分析以及存在的主要问题。第四,总结医药企业的特点,并以此提出一系列综合评价指标,从而建立医药企业并购绩效评价的指标体系。第五,采用案例研究法对HR医药商业集团的并购绩效进行研究,基于因子分析法对所选取的各个指标分析评价,提取三个公共因子并构建综合绩效评分函数。通过对并购前和并购后的绩效进行对比,得出相关结论。评价结果表明：HR医药商业集团的综合并购绩效在并购后一年出现明显的快速下滑,之后逐年呈现缓慢上升的趋势。评价结果同时也证明了多维度选取评价指标的综合优越性以及选取因子分析法评价分析绩效的客观合理性。最后,针对HR医药商业集团和我国医药行业并购提出相关策略,同时说明本文的局限性。研究发现,HR医药商业集团的并购绩效表现缓慢,在并购的当年绩效迅速下降,但是总体来看还是呈上升趋势。
[Abstract]:With the announcement of the new medical reform plan in 2009, the state hopes to speed up the upgrading of the management of the pharmaceutical industry and the improvement of the industrial concentration. Under such an environment, the pharmaceutical companies in our country are showing a trend of merger and acquisition. It is very important to study the comprehensive M & A performance of pharmaceutical enterprises and to evaluate their M & A performance scientifically, which is the key to measure the success of M & A of pharmaceutical enterprises. The evaluation system and system can help enterprises improve their understanding of M & A performance. Only by perfecting the M & A system of enterprises and improving their M & A performance can they truly enhance their core competitiveness. This topic has some theoretical and practical significance. The whole article is divided into six parts. First of all, it mainly introduces the background significance of this thesis. The research contents and methods, innovation points and limitations. Secondly, the concept of M & A is defined, at the same time, the theoretical basis of M & A performance and the domestic and foreign research status of M & A performance are introduced. Third, This paper analyzes the current development of M & A in the pharmaceutical industry of China, including the background of M & A system, the present situation and the main problems. 4th, summarizes the characteristics of pharmaceutical enterprises, and puts forward a series of comprehensive evaluation indexes. Thus, the index system of M & A performance evaluation of pharmaceutical enterprises is established. 5th, the case study method is used to study the M & A performance of HR pharmaceutical commercial group, and the selected indicators are analyzed and evaluated based on factor analysis. Three common factors were extracted and a comprehensive performance scoring function was constructed. The evaluation results show that the performance of comprehensive M & A of the W HR Pharmaceutical Commercial Group declined rapidly in the year after M & A. At the same time, the evaluation results also prove the comprehensive superiority of multi-dimension evaluation index and the objective rationality of selecting factor analysis method to evaluate the performance. This paper puts forward the relevant strategies for the M & A of HR and China's pharmaceutical industry, and explains the limitations of this paper. The research finds that the performance of M & A of HR Pharmaceutical Commercial Group is slow, and the performance of M & A in the year of M & A is declining rapidly. But overall, there is an upward trend.
【学位授予单位】：北京化工大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：F271;F426.72

【参考文献】